Great interest has recently been shown in two new compounds, MDV3100, an antiandrogen specifically designed for use in AR-overexpressing prostate cancer [43], and abiraterone acetate, a CYP17A inhibitor that blocks steroid biosynthesis in the adrenal gland and possibly within the tumor [44]. This evidence concerns the gene AR and Familial prostate cancer.